1. Pink Sheet

PBM Rebates Drive List-To-Net Price Gap For Insulins, Study Shows; More Fodder For Reforms?

 
• By Cathy Kelly

Mandatory government discounts had a much smaller impact on net prices than voluntary rebates in commercial and Medicare Part D plans, researchers determine. The cap on Medicaid rebates, which will be eliminated in 2024, may have contributed to at least some of the disparity.

Study Plumbs Relative Impact Of Price Concessions • Source: Shutterstock

The growth in pharmacy benefit manager-negotiated rebates in Medicare Part D and commercial plans for leading insulin products in recent years underscores how much those concessions have influenced list price increases relative to government-mandated discounts and rebates, according to a new analysis published in JAMA Network Open.

The insulin category is an often-cited example of the disconnect between list and net prices in competitive and highly-rebated categories. (See box, below

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 
• By Neena Brizmohun

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By Vibha Sharma

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.